• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

About FDA

  • Print
  • Share
  • E-mail

Research Project: Drug Deposition in Tissue

Contacts: Dave Saylor and Ji Guo 

Drug-eluting stents (DES) are the treatment of choice for reducing restenosis rates after plaque removal.  Successful innovation of new DES products continues to depend critically on advances in the understanding of key relationships between geometry, flow, drug physicochemical properties and the resulting deposition patterns.  FDA is charged with evaluating how the drug is released and is developing test methods to evaluate both design and manufacturing of new drug releasing medical devices to address whether they release the optimum amount of drug.   

To improve insight into DES performance and to facilitate future innovations, scientists in the Active Materials Lab developed a computational model of drug eluting stents deployed into a diseased blood vessel.  These results were then used to analyze drug elution from the stent into the tissue and to analyze the impact of drug diffusivity and solubility.  This tool is useful for studying the effect of drug physicochemical properties and local transport factors on drug distribution and retention in the vessel wall.  In this way, investigators may determine if a medical device design releases the right amount of drug to be effective vs toxic.  The results of this work will be made available to the DES design community to facilitate future DES development.